Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Open accessThe DOI matches its Crossref record; 220 of the 220 references it cites were found in a registry or an index; 89 of the 278 sources its claims cite were checked for support.
Abstract
Studies on psychotropic medications decrease, discontinuation, or switch have uncovered withdrawal syndromes. The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class (i.e., benzodiazepines, nonbenzodiazepine benzodiazepine receptor agonists, antidepressants, ketamine, antipsychotics, lithium, mood stabilizers) according to the diagnostic criteria of Chouinard and Chouinard [Psychother Psychosom. 2015;84(2):63-71], which encompass new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. All these drugs may induce withdrawal syndromes and rebound upon discontinuation, even with slow tapering. However, only selective serotonin reuptake inhibitors, serotonin noradrenaline reuptake inhibitors, and antipsychotics were consistently also associated with persistent post-withdrawal disorders and potential high severity of symptoms, including alterations of clinical course, whereas the distress associated with benzodiazepines discontinuation appears to be short-lived. As a result, the common belief that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature. Ketamine, and probably its derivatives, may be classified as at high risk for dependence and addiction. Because of the lag phase that has taken place between the introduction of a drug into the market and the description of withdrawal symptoms, caution is needed with the use of newer antidepressants and antipsychotics. Within medication classes, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, and quetiapine are more likely to induce withdrawal. The likelihood of withdrawal manifestations that may be severe and persistent should thus be taken into account in clinical practice and also in children and adolescents.
Overview
CoChat Summary
TL;DR
This overview applies Chouinard and Chouinard’s diagnostic criteria to withdrawal after decrease, discontinuation, or switch of psychotropic medications, distinguishing new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders. It concludes that all reviewed drug classes may induce withdrawal and rebound even with slow tapering, but SSRIs, SNRIs, and antipsychotics are consistently associated with persistent post-withdrawal disorders and potentially high severity, whereas benzodiazepine discontinuation distress appears short-lived.
Key findings
- Withdrawal reactions can occur after abrupt discontinuation or gradual tapering; prevalence was reported as 54% among adults with serious mental illness, and antidepressant withdrawal incidence ranged from 27 to 86% (weighted average 56%). New withdrawal symptoms peak at 36–96 h, last up to 6 weeks, and are usually reversible; rebound symptoms return original symptoms at greater intensity; persistent post-withdrawal disorders last >6 weeks and are potentially irreversible.
- SSRIs, SNRIs, and antipsychotics were consistently associated with persistent post-withdrawal disorders and increased severity, including altered clinical course. Venlafaxine withdrawal rates ranged from 23 to 78%, and levomilnacipran from 9 to 10%. Antipsychotic supersensitivity psychosis prevalence was reported as 65% in a long-acting injectable risperidone study, 26.5% in a retrospective aripiprazole-switch study, and 72% in treatment-resistant schizophrenia patients treated with second-generation antipsychotics.
- Benzodiazepine new withdrawal symptoms are generally mild, transient, and subside within 2–4 weeks; 75% of patients withdrawn after long-term benzodiazepine use developed new withdrawal symptoms regardless of rapid or slow elimination. Rebound anxiety occurred in 5 of 7 (71.4%) bromazepam-treated patients versus 2 of 7 (28.6%) diazepam-treated patients. Persistent post-withdrawal disorders after long-term benzodiazepine use are described, but the literature is “hardly existent.”
- Ketamine and probably its derivatives may be classified as high risk for dependence and addiction; new withdrawal symptoms typically begin within 24 h, last approximately 3 days, and may persist for 2 weeks. Lithium withdrawal evidence is weak and ambiguous, and data on mood stabilizers are limited.
Methods
- Overview/review of the literature; MEDLINE was searched from inception to January 2020, with manual searching of reference lists and relevant reviews. Search terms combined “discontinuation/withdrawal” with drug-class terms (benzodiazepine, Z-drug, antidepressant, ketamine/esketamine, antipsychotic/neuroleptic, lithium, mood stabilizer).
- Eligible articles were English, peer-reviewed papers reporting data on adult subjects who decreased, discontinued, or switched psychotropic medications. Titles and abstracts were screened by 1 reviewer; potentially relevant full reports were independently assessed by 2 reviewers to consensus.
- Withdrawal symptoms were categorized using a previously used antidepressant discontinuation categorization (general, cardiovascular, gastrointestinal, genitourinary, sensory-related, neuromuscular, sexual, and central nervous system symptoms) and classified according to Chouinard and Chouinard’s criteria for new withdrawal symptoms, rebound symptoms, and persistent post-withdrawal disorders.
Limitations
- Stated: evidence for lithium withdrawal is weak and ambiguous; literature on persistent post-withdrawal disorders after long-term benzodiazepine use is hardly existent, and no studies were found on managing benzodiazepine persistent post-withdrawal disorders. No persistent post-withdrawal data are published for Z-drugs, and data are limited for newer antidepressants, carbamazepine, valproate, and lamotrigine; no rebound or persistent post-withdrawal data are available for mood stabilizers.
- Stated: proposed management strategies for SSRI/SNRI withdrawal—including hyperbolically decreasing dose patterns, multistep dose reduction, and Fava and Belaise’s pharmacological/non-pharmacological strategies—need testing in randomized controlled trials. One group CBT trial found only 37% (n = 26) discontinued antidepressants and 28% (n = 20) discontinued without recurrence, though timing and sample vulnerability may have contributed.
- Evident: this is a narrative overview rather than a systematic review or meta-analysis; no formal quality appraisal or risk-of-bias assessment is described, title/abstract screening was done by one reviewer, and conclusions often rely on case reports, online reports, and limited controlled data. The authors also note a lag phase between drug marketing and description of withdrawal symptoms, which limits certainty for newer agents.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
37 Valid · 35 Not valid · 86 Not checked · 19 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“This was confirmed by other studies [53-59].”
What the sources say
- Not checked — no full text of the sourcecites [53] source
- Not checked — no full text of the sourcecites [54] source
- Not checked — no full text of the sourcecites [55] source
- Not checked — no full text of the sourcecites [56] source
- Disputedcites [57] sourceExperimental — accuracy not yet measured
The Discussion (page not specified in our copy) says the study found no evidence of rebound insomnia after abrupt withdrawal of temazepam. Although this paper evaluated a short-term protocol, it does not confirm the attributed finding; it reports the opposite for the benzodiazepine it studied. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [58] source
- Disputedcites [59] sourceExperimental — accuracy not yet measured
The Design section describes nine nights of temazepam followed by three placebo recovery nights. Rather than confirming rebound insomnia after cessation, the Discussion (p. 695) says there was “no consistent disruption of sleep” and that mean sleep time during recovery was similar to baseline, although four of 12 patients had some disturbed recovery nights. (LLM, conf=0.89)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Recently, it has been described the case of a patient in which PSSD symptoms were part of a broader syndrome which was diagnosed as persistent post-withdrawal disorder [129].”
What the sources say
- Could not verifycites [129] sourceExperimental — accuracy not yet measured
The Discussion > Discontinuation symptoms passage concerns ketamine withdrawal, not PSSD or a diagnosis of persistent post-withdrawal disorder. Searches for those terms and for a patient case found no passage in our copy addressing the claimed case. (LLM, conf=0.76)
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“One study found acute dystonia as new withdrawal symptom resulting from abrupt discontinuation of bupropion [105].”
What the sources say
- Could not verifycites [105] sourceExperimental — accuracy not yet measured
The Method and Results (pages unavailable) describe withdrawal reports involving SSRIs and SNRIs, not bupropion. A search for bupropion, acute dystonia, and movement disorders found no passage addressing the claimed symptom after abrupt bupropion discontinuation. (LLM, conf=0.76)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“The evidence for withdrawal after lithium decrease or discontinuation is weak and ambiguous.”
What the sources say
- Could not verifycites [173] sourceExperimental — accuracy not yet measured
Section 2.1 mentions cognitive impairments with lithium and reports withdrawal reactions across psychotropic drugs, but does not assess the evidence for withdrawal specifically after lithium dose reduction or discontinuation. A search for lithium found no passage characterizing that evidence as weak or ambiguous; page numbers were unavailable in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Persistent post-withdrawal disorders, that is a condition in which rebound symptoms and/or new withdrawal symptoms and/or emerging new psychotic symptoms of another type, such as disorganized behavior, persist longer than 6 weeks, have been described after discontinuation of antipsychotics.”
What the sources say
- Could not verifycites [21] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
- Partly supportedcites [22] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [150] source
- Not checked — no full text of the sourcecites [151] source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
91 more claims · 25 with their cited sources checked
Create a free account to see all 177 claims and every source verdict.
- Probably not a substantial claim. 31
- It may state two separate claims as one. 56
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Longer-term BZD use and use of high-dose, rapid-acting BZDs increase the risk of protracted withdrawal”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protracted symptoms persist beyond the expected elimination of the BZD from a patient’s system after discontinuation (e.g., 4–6 weeks), with some patients experiencing these symptoms for months or years.78,130,132”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [130]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In this respect, antidepressants do not differ from other dependence-forming central nervous system (CNS) drugs like benzodiazepines, opioids, gabapentinoids, or psychostimulants.3,19–22”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As with other psychotropics, the potential for antidepressant PWS is embedded in pharmacodynamic adaptations and possibly irreversible neurophysiological alterations following prolonged drug exposure.19,20,31”
From Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Untreated symptoms may be mild and resolve spontaneously in 1–3 weeks; in other cases they may persist for months or even years,40–45 leading to what has been defined as persistent post-withdrawal disorder.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [45]
Experimental — accuracy not yet measured
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
Lazarou, J., Pomeranz, B. H., & Corey, P. N. (1998) · JAMA · doi:10.1001/jama.279.15.1200 · Cited by 4,807
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Reed, G. M., First, M. B., Kogan, C. S., Hyman, S. E., Gureje, O., Gaebel, W., Maj, M., Stein, D. J., Maercker, A., Tyrer, P., et al. (2019) · World Psychiatry · doi:10.1002/wps.20611 · Cited by 765
Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447034 · Cited by 650
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574
Management of Drug and Alcohol Withdrawal
Kosten, T. R., & O'Connor, P. G. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020617 · Cited by 563
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Davies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Withdrawal from long-term benzodiazepine treatment
Petursson, H., & Lader, M. H. (1981) · BMJ · doi:10.1136/bmj.283.6292.643 · Cited by 367
Cited by
Items 101–200 of 263
Mi, W., Meng, M., Xu, F., & Sun, L. (2024) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2024.103044 · Cited by 9
Rennwald, A., & Hengartner, M. P. (2025) · Epidemiology and Psychiatric Sciences · doi:10.1017/s204579602500023x · Cited by 8
“The prolonged use of antidepressant medications, similar to other psychotropic substances, can lead to sustained neurophysiological adaptations (Ashton, 1991; Cosci and Chouinard, 2020; Fava and Cosci, 2019; Horowitz et al. , 2023; Lerner and Klein, 2019).”
InfluentialHidden Costs: The Clinical and Research Pitfalls of Mistaking Antidepressant Withdrawal for Relapse
Horowitz, M. A., & Davies, J. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000542437 · Cited by 7
“Despite the characteristics of her withdrawal being well-documented by experts like Cosci and Chouinard [5], emergency services misdiagnosed her with agitated depression and later a psychotic disorder, leading to in-voluntary treatment with antipsychotics.”
Silberman, E. K., Nardi, A. E., Starčević, V., Balon, R., Cosci, F., Fava, G. A., Salzman, C., Shader, R. I., & Sonino, N. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23com14959 · Cited by 9
Self-citationGedik, K. C., Ortega‐Villa, A. M., Materne, G., Rastegar, A. T., Sanchez, G. A. M., Reinhardt, A., Brogan, P. A., Berkun, Y., Murías, S., Robles, M., et al. (2024) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2023-225463 · Cited by 8
“Serious withdrawal symptoms are well documented in patients withdrawing psycho-pharmaceutics that have short half-lives, including antidepressants and narcotics, 11 12 but this is not generally considered in patients with systemic inflammation.”
Hamlet’s augury: how to manage discontinuation of mood stabilizers in bipolar disorder
Qureshi, M. M., & Young, A. H. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211000612 · Cited by 13
Merino, D., Gérard, A. O., Destère, A., Askenazy-Gittard, F., Drici, M., & Thümmler, S. (2022) · Biomedicines · doi:10.3390/biomedicines10112972 · Cited by 10
Occurrence of involuntary movements after prolonged misuse of zolpidem: a case report
Ricciardulli, S., Lattanzi, L., Barbuti, M., Ceravolo, R., & Perugi, G. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000443 · Cited by 10
Cosci, F., Chouinard, V., & Chouinard, G. (2023) · Psychotherapy and Psychosomatics · doi:10.1159/000530692 · Cited by 7
Self-citationKishi, T., Sakuma, K., Okuya, M., Matsuda, Y., Esumi, S., Hashimoto, Y., Hatano, M., Miyake, N., Miura, I., Miyahara, K., et al. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001264 · Cited by 9
“Fifth, rapid lithium discontinuation might be associated with greater recurrence risk than gradual discontinuation.(51) To answer this clinical question, further studies are needed to examine the recurrence rate in placebo groups of the enriched-design RCTs of lithium.”
BackgroundAbduljabbar, M. H., Althobaiti, Y. S., Alnemari, R. M., Algarni, M. A., Bamaga, A. K., Alharbi, A. S., Serag, A., & Almalki, A. H. (2024) · Luminescence · doi:10.1002/bio.70049 · Cited by 6
Ganz, A. B., Rolnik, B. M., Chakraborty, M., Wilson, J., Tau, C., Sharp, M. H., Reber, D. D., Slavich, G. M., & Snyder, M. P. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.02.034 · Cited by 6
Shapiro, B. B., Kramer, E. N., Khoury, D., & Preda, A. (2023) · Pharmacopsychiatry · doi:10.1055/a-2078-4593 · Cited by 6
van der Wal, J. M., van Borkulo, C. D., Haslbeck, J. M. B., Slofstra, C., Klein, N. S., Blanken, T. F., Deserno, M. K., Lok, A., Nauta, M. H., & Bockting, C. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102329 · Cited by 7
“20 It could be that such changes were mitigated by components of PCT.”
Juneja, K., Afroze, S., Goti, Z., Sahu, S., Asawa, S., Bhuchakra, H. P., Natarajan, B., & Pandey, S. (2024) · Discover Mental Health · doi:10.1007/s44192-024-00077-2 · Cited by 7
Warlick, H., Leon, L., Patel, R., Filoramo, S., Knipe, R., Joubran, E., Levy, A., Nguyen, H., & Rey, J. A. (2022) · Molecular Biology Reports · doi:10.1007/s11033-022-08110-9 · Cited by 6
“Although they are highly effective for short-term clinical use, chronic BZD use has been heavily correlated to complex neuroadaptive brain changes causing tolerance and dependence at therapeutic doses with severe, life-threatening withdrawal symptoms occurring upon discontinuation in some patients [2].”
BackgroundTrazodone once-a-day: A formula for addressing challenges in antidepressant safety and tolerability
Goldberg, J. F., Steinman, M. Q., & Stahl, S. M. (2023) · Neuroscience Applied · doi:10.1016/j.nsa.2023.101127 · Cited by 7
“These reports all predate trazodone OAD, and, to our knowledge, not much is known about withdrawal symptoms associated with this formulation (Cosci and Chouinard, 2020; Otani et al., 1994).”
InfluentialWell-being Therapy in Depressive Disorders
Mansueto, G., & Cosci, F. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_19 · Cited by 8
Self-citationDepression and Anxiety Disorders
Karamustafalıoğlu, O., & Yumrukçal, H. (2025) · Wiley eBooks · doi:10.1002/9781119870203.mpg003.pub2 · Cited by 8
Impact of Abrupt Interruption of Home Psychotropic Medications at ICU Admission
Atherton, J., Abdrabbo, M., & Kassab, H. (2023) · Journal of Pharmacy Technology · doi:10.1177/87551225231182286 · Cited by 6
Segebarth, P. B., Schallmo, M. S., Odum, S. M., Hietpas, K. T., Michalek, C. J., Chapman, T. M., Leas, D. P., Milam, R. A., & Hamid, N. (2024) · Clinical Spine Surgery A Spine Publication · doi:10.1097/bsd.0000000000001608 · Cited by 7
“39,40 Accordingly, any patient who had been using any amount of a gabapentinoid preoperatively was initiated on a weaning protocol at the time of discharge so as to mitigate or avoid the risk of withdrawal once their prescribed regimen was completed.”
Current perspectives and trends in acupuncture for sleep disorders: a bibliometric analysis
Huang, Y., Ying, X., Zhang, J., Hu, R., Chen, Y., Wu, L., Chen, B., Zhang, K., He, K., & Ma, R. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1338455 · Cited by 6
Tang, F., Yang, L., Yang, W., Li, C., Zhang, J., & Liu, J. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01613-x · Cited by 6
Peer support’s role in helping individuals withdraw from psychiatric medications
Maviglia, M. A., Hume, D., & Cooeyate, N. J. (2023) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2023.14.00746 · Cited by 5
Brandt, J. (2024) · BJPsych Advances · doi:10.1192/bja.2022.62 · Cited by 3
Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don’t Know
Silberman, E. K. (2025) · Drugs · doi:10.1007/s40265-025-02261-2 · Cited by 8
“Return or rebound of anxiety-related symptoms is at the core of the benzodiazepine withdrawal syndrome, typically starting hours to days after decreasing or stopping medication that the patient had been receiving at therapeutic doses for at least a month [74].”
Dependence on newer generation antidepressants
Vaaler, A. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0339 · Cited by 4
Lima, V. G., Silva, M. T., Biase, T. M. M. A., & Galvão, T. F. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70136 · Cited by 5
“Antidepressants, like other psychotropic medications, have the potential for misuse or dependence, which can lead to negative health outcomes [22, 23].”
Fava, G. A. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001468 · Cited by 4
Brancati, G. E., Tripodi, B., Novi, M., Barbuti, M., Medda, P., & Perugi, G. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114169 · Cited by 4
Anxiolytics: Misuse, Dependence, and Withdrawal Syndromes
Tang, V. M., & Davies, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_405 · Cited by 4
Hatem, G., Ankouni, A., Salhab, S., et al. (2023) · Journal of Generic Medicines The Business Journal for the Generic Medicines Sector · doi:10.1177/17411343231162561 · Cited by 4
“Avoiding the discontinuation of medication in chronic patients namely those using psychotropics is essential to prevent the deterioration of their mental health.(16) Assessing the characteristics of patients that used generic drugs can help target specific groups in order to promote generic drug use and clarify the as…”
BackgroundQuetiapine-associated thrombocytopenic purpura in a young man with a first episode schizophrenia
Fekih‐Romdhane, F., Jenhani, R., Cherif, W., et al. (2022) · L Encéphale · doi:10.1016/j.encep.2021.12.006 · Cited by 4
Explainable drug side effect prediction via biologically informed graph neural networkPreprint
Huang, T., Lin, K., Machado‐Vieira, R., Soares, J. C., Jiang, X., & Kim, Y. (2023) · medRxiv · doi:10.1101/2023.05.26.23290615 · Cited by 4
“These uncommon SEs can also be very critical and sometimes they cause post-market drug withdrawals 38 .”
BackgroundSu, Z., Huang, Z., Chen, X., & Li, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1465245 · Cited by 3
Xin, Q., Paudel, D., Zhang, J., Wei, H., Cheng, Y., Xu, Y., Fang, R., Jiang, J., Wang, Y., & Zhang, B. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05142-z · Cited by 4
“In addition, the use of antidepressants might have side effects and withdrawal reactions after discontinuation [20, 21].”
Psychofarmaca en de behandeling van slaapstoornissen
van Veen, M., Kamphuis, J., & der Lek, R. F. R. (2020) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-2524-5_19 · Cited by 3
Strawbridge, R., Myrtle, S., Carmellini, P., Hampsey, E., Cousins, D. A., & Young, A. H. (2025) · The Canadian Journal of Psychiatry · doi:10.1177/07067437251328282 · Cited by 3
“33,34 Frequent adverse effect reporting is not clearly attributable to the intervention of study 35 and our result may be partially a nocebo effect due to, for example, expectation of side effects (given lithium ’ s reputation), pre-existing symptoms, and/or speci fi c provided suggestions in this…”
Huang, W., Li, X., Huang, S., Huang, S., Xia, H., Guo, Z., Yan, H., Li, Y., & Shang, D. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103893 · Cited by 3
Kim, J., Stewart, R. J., Kang, H., Kim, J., Lee, J., Ms, J., Lee, J.-Y., Kim, S., & Shin, I. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.06.015 · Cited by 5
Potla, S., AlQabandi, Y., Nandula, S. A., Boddepalli, C. S., Gutlapalli, S. D., Lavu, V. K., Abdelwahab, R. A. M., Huang, R., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.34746 · Cited by 5
Liu, D., Zhang, Q., Zhao, Z., Chen, M., Hou, Y., Wang, G., Shen, H., Zhu, H., Ji, Y., Ruan, L., et al. (2023) · Healthcare · doi:10.3390/healthcare11040554 · Cited by 5
“However, the new SSRIs and SNRIs have similar problems of withdrawal and rebound as BZDs, which had been reported in many studies [26,27].”
ResultInnovative Strategies in Evaluation and Treatment of Burnout in Medical Workers
Guidi, J., & Fava, G. A. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000541309 · Cited by 4
“In most of the cases, the bene fi ts of these medications are questionable at best, while substantial adverse effects may ensue in the long term [37, 38].”
The broad spectrum of malignant syndromes
Cuccarelli, M., Zampogna, A., & Suppa, A. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106734 · Cited by 7
Chapoutot, M., Meloni, F., Peter‐Derex, L., Bastuji, H., Leslie, W., Schoendorff, B., Heinzer, R. C., Nicolas, A., Higgins, S., Bourgeois, A., et al. (2025) · Journal of Behavioral and Cognitive Therapy · doi:10.1016/j.jbct.2025.100533 · Cited by 6
Ho, S., & Wong, A. V.-K. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001041 · Cited by 3
Missbrauch und Abhängigkeit von Benzodiazepinen und Z-Drugs: Klinik und Therapie
Soyka, M. (2021) · Nervenheilkunde · doi:10.1055/a-1523-5718 · Cited by 7
“Antidepressiva werden auch sonst in der Behandlung der BZD-Abhängigkeit häufig eingesetzt, durchaus mit gemischten Ergebnissen [95, 96].”
BackgroundWhen Withdrawal Symptoms Change the Meaning of Research Data
Cosci, F., Chouinard, V., & Chouinard, G. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000522241 · Cited by 3
Self-citationSECOND TO NONE – RATIONALE, TIMING, AND CLINICAL MANAGEMENT OF CLOZAPINE USE IN SCHIZOPHRENIAPreprint
Qubad, M., & Bittner, R. A. (2022) · doi:10.31234/osf.io/jfc6w · Cited by 3
Wang, Y., Zhang, Z., Ye, Y., Xu, J., & Zhou, J. (2025) · BMC Psychology · doi:10.1186/s40359-025-02722-z · Cited by 3
“…treatment model (involving pharmacological interventions during the acute phase of depression and psychotherapy during the residual phase) [86, 87] may provide clinicians with an effective approach to alleviating depressive symptoms associated with psychotic experiences in survivors of…”
Tao, Y., Xu, J., Liu, Z., Huang, Z., Wang, F., Xia, M., & Chen, Y. (2025) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2025.112335 · Cited by 2
Torshin, I. Y., Громова, О. А., & Лиманова, О. А. (2022) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2022-5-60-68 · Cited by 2
Maviglia, M. A., & Cooeyate, N. J. (2024) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2024.15.00762 · Cited by 3
Effect of prophylactic perphenazine on delirium after extubation in severe acute pancreatitis
Chen, M., Yu, M., Zhang, D., Chen, Y., Yang, Z., Chen, E., Mao, E., & Ni, T. (2024) · European journal of medical research · doi:10.1186/s40001-024-02158-y · Cited by 2
Hata, E., Miyauchi, M., Noguchi, N., & Asami, T. (2025) · BMC Psychiatry · doi:10.1186/s12888-024-06456-x · Cited by 2
“Gradual dose reduction is recommended to minimize these risks [10].”
Neurobiological Mechanisms of Ketamine Use, its Addiction, and Withdrawal: A Mini Review
Ng, S. H., Lee, Y. Z., Hong, M. Y., Kow, A. S. F., d’Arqom, A., Tham, C. L., Ho, Y., & Lee, M. T. (2025) · Current Clinical Pharmacology · doi:10.2174/0127724328362434250224105609 · Cited by 4
Downey, P. M., Collins, J. C., El‐Den, S., & O’Reilly, C. L. (2025) · International Journal of Social Psychiatry · doi:10.1177/00207640251384126 · Cited by 4
“Certain psychotropic medications, such as SSRIs and antipsychotics, can cause physical dependence, necessitating a gradual dose reduction to avoid withdrawal symptoms (Cosci & Chouinard, 2020).”
Yeh, J., Lai, M.-C., Yang, Y., Hsu, C. Y., & Kao, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.797623 · Cited by 4
Soyka, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00033-5 · Cited by 3
Ng, V. W. S., Gao, L., Chan, E. W., Lee, E. H. M., Hayes, J., Osborn, D., Rainer, T. H., Man, K. K. C., & Wong, I. C. K. (2022) · Psychological Medicine · doi:10.1017/s0033291722002215 · Cited by 2
“…injuries in patients with BPD. Discontinuation of long-term psychotropic medications regimen has been a common clinical occurrence among patients with BPD and is usually followed by a range of withdrawal reactions that could arise within hours or days (Cosci & Chouinard, 2020; Kishi et al., 2020).”
BackgroundAlthobaiti, Y. S. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.10.010 · Cited by 2
“Notably, withdrawal symptoms are very common after abrupt discontinuation of psychotropic medications (Brandt et al., 2020; Cosci and Chouinard, 2020).”
Is the serotonin hypothesis dead? If so, how will clinical psychology respond?
Borgogna, N., & Aita, S. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.1027375 · Cited by 2
“Indeed, even if serotonin re-uptake inhibition is not curing depressive symptoms, withdrawal associated with SSRI discontinuation may disrupt neural systems causing harmful side effects (Cosci and Chouinard, 2020; Massabki and Abi-Jaoude, 2021).”
BackgroundLixia, L. I., Kejun, D. O. N. G., Chen, C. H. E. N., et al. (2022) · Journal of the Faculty of Agriculture Kyushu University · doi:10.5109/4797825 · Cited by 2
Benzodiazepines in elderly patients
Fava, G. A. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13619 · Cited by 4
“Second, withdrawal reactions may occur after discontinuation of both benzodiazepines and antidepressants, but for the latter such events appear to be more troublesome and persistent.(5) Third, the ghost of dementia evoked in observational studies did not manifest its presence when carefully conducted methodological in…”
BackgroundFava, G. A. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000511544 · Cited by 2
Huff, C. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000514045 · Cited by 2
Pharmacological management of psychoactive substance withdrawal syndrome
Fluyau, D., Cook, S., Chima, A., Kailasam, V. K., & Revadigar, N. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00874-7 · Cited by 2
Chang, C., Hayes, R. D., Broadbent, M. T. M., Shetty, H., Su, Y., Meesters, P. D., & Stewart, R. J. (2024) · BJPsych Open · doi:10.1192/bjo.2024.765 · Cited by 2
“16 17 – 23 Among people with SMI, unnatural causes of death (i.e. homicide and suicide) have been found to be of particular importance, especially for those who died at a younger age.”
BackgroundJalsrai, A., Altangerel, A., Urtnasan, M., & Hsiu, M. H.-L. (2025) · Journal of Medicinal Plants Research · doi:10.5897/jmpr2025.7382 · Cited by 1
Hyperbolic tapering of antidepressants: where are we now?
Horowitz, M. A., & Wilcock, M. (2025) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2024.000065 · Cited by 1
“14 18 Recent analyses have estimated that the risk of protracted withdrawal from antidepressants may be as high as 15%.”
Koskinen, J., Hakko, H. H., Riipinen, P. K., Sihvola, N., & Halt, A. (2025) · European Journal of Public Health · doi:10.1093/eurpub/ckaf263 · Cited by 1
“The possibility of medication withdrawal as a potential contributor to fatal motor vehicle accidents needs to be considered; the use of antipsychotics and certain other psychotropics pose a risk of post-withdrawal disorders and potential high severity of symptoms [26].”
Eserian, J. K., de Oliveira, F. F., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2026) · The British Journal of Psychiatry · doi:10.1192/bjp.2026.10663 · Cited by 1
Louie, K., Jauhar, S., Rubio, J., Brand, B. A., Pillinger, T., Howes, O. D., & McCutcheon, R. A. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00225-7 · Cited by 2
Lithium Hemodialysis Removal-Related Recurrent Manic Episode in a Bipolar Patient
Lin, H., Kung, F.-H., Tai, Y., Huang, S., Hsu, Y., & Tzeng, N. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001382 · Cited by 1
Recreational Drugs and Men’s Health
Chengodu, T., & Lawrentschuk, N. (2022) · Springer eBooks · doi:10.1007/978-3-030-84752-4_12 · Cited by 3
Nobre, M., & Kurihara, A. C. Z. S. (2023) · African journal of rhetoric · doi:10.21134/haaj.v23i1.721 · Cited by 1
Sudden onset catatonia following tricyclic antidepressant withdrawal - A case report
Sharma, N., Naskar, C., Sharma, K., et al. (2023) · Indian Journal of Psychiatry · doi:10.4103/indianjpsychiatry.indianjpsychiatry_679_23 · Cited by 1
“[1] However, no information is available about the occurrence of withdrawal catatonia with TCAs.”
Gomes, L. D. S., Pereira, B. R. A., Dias, L. M. F., Mesquita, J. L., Passos, B. V. D. S., & Sousa, M. (2024) · Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde · doi:10.30968/rbfhss.2024.151.1020
Maviglia, M. A., Cooeyate, N. J., Hume, D., & Guerra, L. (2024) · Journal of Psychology & Clinical Psychiatry · doi:10.15406/jpcpy.2024.15.00793 · Cited by 1
Dutta, S., Chatterjee, S., Ghosh, S., Basu, B., Prajapati, B. G., & Ali, N. (2025) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-025-09936-z · Cited by 4
“All these consequences have an impact on adherence to therapy [5].”
Persistent Postwithdrawal Syndrome after Benzodiazepine Discontinuation. A Reply to Huff
Cosci, F., & Chouinard, G. (2021) · Psychotherapy and Psychosomatics · doi:10.1159/000515015 · Cited by 1
Self-citationHaghparast, P., Maroney, M. E., Salwan, A., & Sabbaugh, A. (2021) · Side effects of drugs annual · doi:10.1016/bs.seda.2021.08.010 · Cited by 3
The government has a moral duty to help those harmed by prescribed dependence forming drugs
British Medical Journal Publishing Group (2023) · BMJ · doi:10.1136/bmj.p1417 · Cited by 1
Depression and Anxiety Disorders
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg003 · Cited by 1
Treating Depression in Clinical Practice: New Insights on the Multidisciplinary Use of TradozonePreprint
Albert, U., Tomasetti, C., Marra, C., Neviani, F., Pirani, A., Taddeo, D., Zanetti, O. O., & Maina, G. (2023) · Preprints.org · doi:10.20944/preprints202302.0380.v1
Morris, P. (2024) · Qeios · doi:10.32388/c6pqe4.2 · Cited by 1
Louie, K., Jauhar, S., Rubio, J. M., Brand, B. A., Pillinger, T., Howes, O. D., & McCutcheon, R. A. (2026) · medRxiv · doi:10.64898/2026.01.19.26344378 · Cited by 1
Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887
“The benzodiazepine withdrawal syndrome (Brunner et al., 2025; Cosci & Chouinard, 2020; Ng et al., 2018; Sokya, 2017) Psychological Medicine psychiatric disorder, thereby perpetuating unnecessary long-term treatment (Markota, Rummans, Bostwick, & Lapid, 2016; Moore, Pariente, & Begaud, 2015).”
Pandiyammal, V., & Raja, U. K. (2020) · Malaya Journal of Matematik · doi:10.26637/mjm0804/0084
Anxiolytics: Misuse, Dependence, and Withdrawal Syndromes
Tang, V. M., & Davies, S. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_405-1
Psychiatric Comorbidity Populations
Long, L. J., Smith, L. J., & Gallagher, M. W. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818697-8.00196-5
Boesen, K., Paludan‐Müller, A. S., & Ioannidis, J. P. A. (2021) · medRxiv · doi:10.1101/2021.12.07.21267067
Galani, V., Besson, M. J., Chytas, V., Hénaff, C. L., & Prada, P. (2022) · JMIG · doi:10.53738/revmed.2022.18.769.276
Serious states induced by taking psychopharmacs and their treatment
Češková, E., & Horská, K. (2023) · Psychiatrie pro praxi · doi:10.36290/psy.2023.015
Hasler, F. (2023) · transcript Verlag eBooks · doi:10.14361/9783839445716 · Cited by 3
Juneja, K., Afroze, S., Goti, Z., Sahu, S., Asawa, S., Priya, B. H., Natarajan, B., & Pandey, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3374935/v1
Evaluation of the Short-Term Response in Refractory Trigeminal Neuralgia Treated With CyberKnife
Fernandez, A., Aquino, R. E., Guzmán, C. N. D., Díaz, L. M., Mera, M., & Solarte, H. (2023) · Cureus · doi:10.7759/cureus.48401
Prust, R. A. F., & Pavesi, E. (2023) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v35i1.15208
Rocky, N. A. R. M., & Chemi, N. B. (2023) · The Malaysian Journal of Nursing · doi:10.31674/mjn.2023.v15isupp1.003
Hypnotic Dependence and Withdrawal
Brasil, I. S. P. S., & Hasan, R. (2024) · Springer eBooks · doi:10.1007/978-3-031-50710-6_6
Metadata
- Authors
- Cosci, F., & Chouinard, G.
- Affiliations
- Maastricht University (NL)
- McGill University (CA)
- ORCID
- Cosci, Fiammetta
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2020
- Volume
- 89
- Issue
- 5
- Pages
- 283-306
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3014423675
- Cited by
- 265
- References
- 219
- Citations by year
- 2026: 35 · 2025: 34 · 2024: 53 · 2023: 45 · 2022: 37 · 2021: 45 · 2020: 16
- FWCI
- 4.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Florence Research (University of Florence) (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- drug discontinuation, benzodiazepines, antidepressants, ketamine, antipsychotic drugs, lithium, mood stabilizers, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, alprazolam, lorazepam, triazolam, paroxetine, venlafaxine, fluphenazine, perphenazine, clozapine, quetiapine, drug addiction, children and adolescents
- MeSH terms
- Mental Disorders, Humans, Psychotropic Drugs, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.